About: Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $6.75 (+0.90%)
RNAC NASDAQ Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc. share price
Atividade de preço de RNAC
Último preço
$ 6,750
Variação (24h)
0,06 USD (0,90%)
Volume
112.26K
Volume (média 4 sem.)
-
Abertura
$ 6,93
Variação do dia
$ 6,63 - $ 6,97
Fechamento anterior
$ 6,69
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
RNAC price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals